Literature DB >> 33752729

Impact of sex in the prevalence and progression of glioblastomas: the role of gonadal steroid hormones.

Claudia Bello-Alvarez1, Ignacio Camacho-Arroyo2.   

Abstract

BACKGROUND: As in other types of cancers, sex is an essential factor in the origin and progression of glioblastomas. Research in the field of endocrinology and cancer suggests that gonadal steroid hormones play an important role in the progression and prevalence of glioblastomas. In the present review, we aim to discuss the actions and mechanism triggered by gonadal steroid hormones in glioblastomas. MAIN BODY: Glioblastoma is the most common malignant primary brain tumor. According to the epidemiological data, glioblastomas are more frequent in men than in women in a 1.6/1 proportion both in children and adults. This evidence, and the knowledge about sex influence over the prevalence of countless diseases, suggest that male gonadal steroid hormones, such as testosterone, promote glioblastomas growth. In contrast, a protective role of female gonadal steroid hormones (estradiol and progesterone) against glioblastomas has been questioned. Several pieces of evidence demonstrate a variety of effects induced by female and male gonadal steroid hormones in glioblastomas. Several studies indicate that pregnancy, a physiological state with the highest progesterone and estradiol levels, accelerates the progression of low-grade astrocytomas to glioblastomas and increases the symptoms associated with these tumors. In vitro studies have demonstrated that progesterone has a dual role in glioblastoma cells: physiological concentrations promote cell proliferation, migration, and invasion while very high doses (out physiological range) reduce cell proliferation and increases cell death.
CONCLUSION: Gonadal steroid hormones can stimulate the progression of glioblastomas through the increase in proliferation, migration, and invasion. However, the effects mentioned above depend on the concentrations of these hormones and the receptor involved in hormone actions. Estradiol and progesterone can exert promoter or protective effects while the role of testosterone has been always associated to glioblastomas progression.

Entities:  

Keywords:  Estradiol; Glioblastoma; Prevalence; Progesterone; Progression; Sex differences; Testosterone

Mesh:

Substances:

Year:  2021        PMID: 33752729      PMCID: PMC7986260          DOI: 10.1186/s13293-021-00372-5

Source DB:  PubMed          Journal:  Biol Sex Differ        ISSN: 2042-6410            Impact factor:   5.027


  108 in total

1.  Update on the effect of exogenous hormone use on glioma risk in women: a meta-analysis of case-control and cohort studies.

Authors:  Yu-Long Lan; Xun Wang; Jia-Cheng Lou; Bin-Bin Ma; Jin-Shan Xing; Shuang Zou; Bo Zhang
Journal:  J Neurooncol       Date:  2017-12-26       Impact factor: 4.130

Review 2.  Do steroid hormones play a role in the etiology of glioma?

Authors:  Geoffrey C Kabat; Anne M Etgen; Thomas E Rohan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-09-14       Impact factor: 4.254

3.  Evidence that Mifepristone, a progesterone receptor antagonist, can cross the blood brain barrier and provide palliative benefits for glioblastoma multiforme grade IV.

Authors:  Jerome H Check; Carrie Wilson; Rachael Cohen; Mojirayo Sarumi
Journal:  Anticancer Res       Date:  2014-05       Impact factor: 2.480

4.  Estrogen receptor beta (ERbeta) is expressed in brain astrocytic tumors and declines with dedifferentiation of the neoplasm.

Authors:  Anna Batistatou; Dimitrios Stefanou; Anna Goussia; Evdokia Arkoumani; Athanasios G Papavassiliou; Niki J Agnantis
Journal:  J Cancer Res Clin Oncol       Date:  2004-07       Impact factor: 4.553

5.  Regulation of progesterone receptor isoforms content in human astrocytoma cell lines.

Authors:  Edith Cabrera-Muñoz; Aliesha González-Arenas; Milena Saqui-Salces; Javier Camacho; Fernando Larrea; Rocío García-Becerra; Ignacio Camacho-Arroyo
Journal:  J Steroid Biochem Mol Biol       Date:  2008-11-27       Impact factor: 4.292

6.  Trophic effects of estradiol on fetal rat hypothalamic neurons.

Authors:  J A Chowen; I Torres-Alemán; L M García-Segura
Journal:  Neuroendocrinology       Date:  1992-12       Impact factor: 4.914

Review 7.  Sex hormones and immune dimorphism.

Authors:  Aruna Bhatia; Harmandeep Kaur Sekhon; Gurpreet Kaur
Journal:  ScientificWorldJournal       Date:  2014-11-17

8.  Expression of estrogen receptors and androgen receptor and their clinical significance in gastric cancer.

Authors:  Wenbo Tang; Rujiao Liu; Yan Yan; Xiaoli Pan; Minjun Wang; Xiaotian Han; Hui Ren; Zhe Zhang
Journal:  Oncotarget       Date:  2017-06-20

9.  Proliferative and Invasive Effects of Progesterone-Induced Blocking Factor in Human Glioblastoma Cells.

Authors:  Araceli Gutiérrez-Rodríguez; Valeria Hansberg-Pastor; Ignacio Camacho-Arroyo
Journal:  Biomed Res Int       Date:  2017-01-12       Impact factor: 3.411

10.  X-linked severe combined immunodeficiency syndrome: the first Korean case with gamma c chain gene mutation and subsequent genetic counseling.

Authors:  Eun-Kyeong Jo; Satoru Kumaki; Du Wei; Shigeru Tsuchiya; Hirokazu Kanegane; Chang-Hwa Song; Ha Young Noh; Young Ok Kim; So Yeon Kim; Hae Yul Chung; Yoon Ha Kim; Hoon Kook
Journal:  J Korean Med Sci       Date:  2004-02       Impact factor: 2.153

View more
  3 in total

1.  Allopregnanolone Promotes Migration and Invasion of Human Glioblastoma Cells through the Protein Tyrosine Kinase c-Src Activation.

Authors:  Carmen J Zamora-Sánchez; Claudia Bello-Alvarez; Mauricio Rodríguez-Dorantes; Ignacio Camacho-Arroyo
Journal:  Int J Mol Sci       Date:  2022-04-30       Impact factor: 6.208

2.  Prognostic value of immune-related genes and comparative analysis of immune cell infiltration in lung adenocarcinoma: sex differences.

Authors:  Tao Fan; Chunxiang Li; Jie He
Journal:  Biol Sex Differ       Date:  2021-12-04       Impact factor: 5.027

3.  Oral Contraceptive and Glioma Risk: A Prospective Cohort Study and Meta-Analysis.

Authors:  Chuan Shao; Hui Tang; Xiaoya Wang; Jiaquan He; Pan Wang; Nan Wu
Journal:  Front Public Health       Date:  2022-07-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.